Effect of Trimetazidine on Myocardial Salvage Index in Patients with Acute ST Segment Elevation Myocardial Infarction Undergoing Primary PCI

Thesis

Submitted for partial fulfillment of Master Degree in Cardiology

By

Islam Mahmoud Bastawy Ismaiel

MB.B.Ch, Faculty of Medicine Ain Shams University

Under Supervision of

Prof. Dr./ Saeed Abdel Hafez Khaled

Professor of Cardiology
Faculty of Medicine – Ain Shams University

Dr./ Khaled Ahmed Foad

Lecturer of Cardiology
Faculty of Medicine – Ain Shams University

Dr./ Ahmed Mohamed Elmahmoudy

Lecturer of Cardiology Faculty of Medicine – Ain Shams University

Faculty of Medicine
Ain –Shams University
2011

تأثير عقار ترايميتازيدين على معامل إنقاذ عضلة القلب في مرضي إحتشاء عضلة القلب المصحوب بارتفاع في قطعة س- ت في رسم القلب الكهربي والذين تمت إعادة التروية لهم عن طريق القسطرة التداخلية الأولية

رسالة

مقدمة توطئة للحصول على درجة الماجستير في أمراض القلب و الأوعية الدموية

مقدمة من

طبيب/ إسلام محمود بسطاوي اسماعيل بكالوريوس الطب و الجراحة

تحت إشراف

الأستاذ الدكتور/ سعيد عبد الحفيظ خالد أستاذ أمراض القلب و الأوعية الدموية كلية الطب- جامعة عين شمس

الدكتور/ خالد أحمد فواد مدرس أمراض القلب و الأوعية الدموية كلية الطب- جامعة عين شمس

الدكتور/ أحمد محمد المحمودي مدرس أمراض القلب و الأوعية الدموية كلية الطب- جامعة عين شمس

> كلية الطب جامعة عين شمس ٢٠١١

Summary

Acute STEMI is the most serious presentation of CAD carrying the most hazardous consequences and it is caused by occlusion of major coronary artery with primary goal in the management to start reperfusion therapy as early as possible.

Restoration of the coronary flow facilitates cardiomyocyte salvage and decreases cardiac morbidity and mortality. However, reperfusion may result in paradoxical cardiomyocyte dysfunction, a phenomenon termed reperfusion injury.

Trimetazidine is a metabolic anti-ischemic drug which is beneficial in reducing peri-procedural myocardial reperfusion injury.

The aim of the work is to study the effect of trimetazidine on myocardial salvage index in patients with acute STEMI who underwent primary PCI.

This study was conducted on forty patients presented to Ain Shams university hospital by acute STEMI eligible for reperfusion therapy within the period between September 2010 and July 2011.

All patients underwent primary PCI after diagnostic coronary angiography, the IRA was identified and treated using bare metal stents \pm pre-dilatation by balloons according to discretion of treating physician.

بِسْمِ اللهِ الرَّحْمنِ الرَّحِيمِ وما أوتيتم من العلم إلا قليلً

صدق الله العظيم الإسراء .. آية رقم • ^

Acknowledgement

First and foremost, thanks for ALLAH for guiding and helping me to finish this work

I would like to express my sincere gratitude to **Prof. Dr. Saeed Abdel Hafez Khaled,** Professor of Cardiology, Ain Shams University, for his encouragement, support and kindness which enable me to produce good valuable work.

A special tribute and appreciation to **Dr. Khaled**Ahmed Foad, Lecturer of Cardiology, Ain Shams University,
for his active guidance and keen supervision which were of
great help throughout this work.

I would like to express my deepest thanks to Dr. Ahmed Mohamed Elmahmoudy, Lecturer of Cardiology, Ain Shams University, for his uninterrupted care and advice, his meticulous supervision, precious remarks and continuous encouragement.

I would also like to record my thanks and sincere gratitude to my family, my colleagues, physicians of the gamma camera lab., and nursing staff in our Cardiology department for their sincere cooperation.

List of Contents

| List of tables | <i>i</i> |
|--------------------------------------|----------|
| List of figures | iii |
| List of abbreviations | v |
| Introduction | 1 |
| Aim of the work | 3 |
| Review of Literature | |
| - AMI | 4 |
| - Myocardial reperfusion | 8 |
| - Assessment of reperfusion | 22 |
| - Reperfusion injury | 31 |
| - Myocardial Perfusion Imaging (MPI) | 50 |
| - Trimetazidine | 58 |
| Patients and Methods | 63 |
| Discussion | 86 |
| Conclusion | 92 |
| Recommendations | 93 |
| Summary | 94 |
| References | 97 |
| Appendix | I |
| Arabic summary | _ |

List of Tables

| Table No | o. Title | Page |
|--------------------|--|----------------------------|
| No. | | |
| Table (1): | Distribution of ECG changes in STEMI | 6 |
| Table (2): | Doses of fibrinolytics | 10 |
| Table (3): | Fibrinolytics commonly used in STEMI | 11 |
| Table (4): | Contraindications of fibrinolytics | 12 |
| Table (5): | MBG and TIMI myocardial perfusion grade | |
| Table (6): | Basic characteristics of the whole stude population. | - |
| Table (7): | Comparison between patients who received trimetazidine before primar PCI and patients who did not received trimetazidine before primary PCI as regards age, sex, risk factors for CAD | y ge as |
| Table (8): | Comparison between patients who received trimetazidine before primar PCI and patients who did not received trimetazidine before primary PCI as regards post procedural TIMI flow | y ve as |
| Table (9): | Comparison between patients who received trimetazidine before primare PCI and patients who did not receive trimetazidine before primary PCI as regards the initial perfusion defect, the final perfusion defect and the myocardical salvage index. | ry ve as ae al |
| Table (10): | Correlation between post procedure TIMI flow and myocardial salvage inde in both groups. | ex |

| Table (11): | Comparison of initial perfusion defect, final infarction size and myocardial salvage index between the 2 groups in patients with post procedural TIMI 2 flow | 79 |
|--------------------|---|----|
| Table (12): | Comparison of initial perfusion defect, final infarction size and myocardial salvage index between the 2 groups in patients with post procedural TIMI 3 flow. | 81 |

List of Figures

| Figure N | lo. Title | Page |
|---------------------|---|------|
| No. | | |
| Figure (1): | Reperfusion strategies | 21 |
| Figure (2): | Thrombus aspirated from an occluded coronary artery during primary PCI | 21 |
| Figure (3): | Primary PCI for inferior STEMI | 21 |
| Figure (4): | Major Mediators of Lethal Reperfusion Injury | 36 |
| Figure (5): | Mitochondrial PTP | 40 |
| Figure (6): | New cardio-protective strategies for reducing lethal reperfusion injury | 48 |
| Figure (7): | Standard tomographic heart slices, orientated at 90° angles to each other | 54 |
| Figure (8): | Standard segmental myocardial display for semi quantitative visual analysis in a 17-segment model, with corresponding vascular territory schematic | 70 |
| Figure (9): | Comparison between both groups as regards initial size of infarction, final size of infarction and myocardial salvage index. | 77 |
| Figure (10): | Comparison of myocardial salvage index in group 1 between patients with post procedural TIMI 2 and TIMI 3 patients | 78 |
| Figure (11): | Comparison of myocardial salvage index in group 2 between patients with post procedural TIMI 2 and TIMI 3 patients | |
| Figure (12): | Comparison between both groups as regards initial size of infarction, final size of infarction and myocardial salvage | |

| | TIMI 2 flow | 80 |
|---------------------|---|----|
| Figure (13): | Comparison between both groups as regards initial size of infarction, final size of infarction and myocardial salvage index in patients with post procedural TIMI 3 flow. | 81 |
| Figure (14): | The calculation of the initial and final size of infarction in patient number "16" in the study group. | 82 |
| Figure (15): | The 4 D M SPECT images of patient number "16" in the study group before and after reperfusion. | 83 |
| Figure (16): | The calculation of the initial and final size of infarction in patient number "5" in the control group | 84 |
| Figure (17): | The 4 D M SPECT images of patient number "5" in the control group before and after reperfusion | 85 |

List of Abbreviations

AIVR : Accelerated idioventricular rhythm

AMI : Acute myocardial infarction
 ATP : Adenosine tri-phosphate
 ATPase : Adenosine tri-phosphatase

CABG : Coronary artery bypass grafting

CAD : Coronary artery diseaseCCU : Coronary care unit

CD : Cluster of differentiation

CK : Creatine kinase

CK-MB : Creatine kinase myocardial bandcTFC : Corrected TIMI frame count

cTnI : Cardiac troponin IcTnT : Cardiac troponin T

ECG : Electrocardiographic, Electrocardiogram

ESC : European Society of CardiologyFDA : Food and drug administration

FMC: First medical contact

GP : Glycoprotein

HLA : Horizontal long axis
IRA : Infarct related artery
IU : International unit
Kev : Kilo electron volt

LAD : Left anterior descending artery

LBBB : Left bundle branch blockLCX : Left circumflex artery

LV : Left ventricle, left ventricularMAC : Membrane attack complexMBG : Myocardial blush grade

MCE : Myocardial Contrast echocardiography

mCi : Milli Curie
mg : Milligram
mm : Millimeter

MPI : Myocardial perfusion imaging

mv : Millivolt

NAD : Nicotine amide adenine dinucleotidePCI : Percutaneous coronary intervention

PDH : Pyruvate dehydrogenase

pH : Power of hydrogen

PIS : Pre-infarction syndrome

PMNs : Polymorph nuclear leukocytes

PTCA: Percutaneous transluminal coronary angioplasty

PTP : Permeability transition pore

RCA: Right coronary artery

RISK : Reperfusion injury salvage kinase

r-PA : Reteplase S : Second

SD : Standard deviation

SK : Streptokinase

SPECT : Single photon emission computed tomographySTEMI : ST segment elevation myocardial infarction

Tc : Technetium

TIMI: Thrombolysis in myocardial infarction

TNF: Tumor necrosis factor

TNK-tPA: Tenecteplase

tPA : Tissue plasminogen activator

VLA : Vertical long axis

Vs. : Versus

Introduction

Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. Myocardial infarction occurs when irreversible myocardial cell damage or death occurs.

ST segment elevation myocardial infarction (STEMI) is the most serious presentation of atherosclerotic coronary artery disease (CAD) carrying the most hazardous consequences and it is caused by occlusion of major coronary artery ⁽¹⁾.

Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy especially when performed by an experienced team within the shortest possible time from first medical contact (FMC) ⁽²⁾.

One of the main aims of all treatment modalities in STEMI is mortality reduction, and since the use of mortality as an end point in randomized trials of reperfusion therapy requires increasingly large sample sizes, there has been a growing interest in assessment of infarct size by technetium (Tc)-99m sestamibi single photon emission computed tomography (SPECT) imaging as a surrogate end point for both early and late mortality ⁽³⁾.

On the basis of the available scientific evidence, SPECT imaging with Tc-99m sestamibi is the best available measurement tool for infarct size in clinical medicine.Tc-99m

sestamibi scintigraphy is considered a reliable method to assess myocardial salvage (difference between the actual and potential infarct size) achieved by reperfusion therapy ⁽³⁾.

Trimetazidine is a metabolic anti-ischemic drug that exerts its beneficial effects without altering hemodynamic function of the heart. It acts by optimizing cardiac metabolism by reducing fatty acid oxidation through selective inhibition of mitochondrial 3-ketoacyl coenzyme A thiolase so it decreases ischemic stress and improves cardiac performance and also it showed cytoprotective effect in several models of myocardial infarction ⁽⁴⁾.

Trimetazidine is beneficial in reducing peri-procedural myocardial reperfusion injury in elective PCI (5).

Aim of the work

To assess the effect of trimetazidine on myocardial salvage index in patients with STEMI undergoing primary PCI.